PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
Abstract
Authors
J. Robert S. Culine M. Roupret Y. Zhong V.S. Prabhu R. Xu H. Li A. Lafuma L. Bensimon A. Clement